Elicio Therapeutics’ (ELTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Elicio Therapeutics (NASDAQ:ELTX) in a research report released on Tuesday morning, Marketbeat.com reports. HC Wainwright also issued estimates for Elicio Therapeutics’ Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.83) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.38) EPS.

Several other analysts have also commented on ELTX. Rodman & Renshaw reaffirmed a “buy” rating on shares of Elicio Therapeutics in a research report on Monday, June 15th. Wall Street Zen raised shares of Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings lowered shares of Elicio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. B. Riley Financial began coverage on shares of Elicio Therapeutics in a research note on Wednesday, June 10th. They set a “buy” rating and a $27.00 price target for the company. Finally, LADENBURG THALM/SH SH started coverage on shares of Elicio Therapeutics in a report on Thursday, June 18th. They issued a “buy” rating and a $12.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Elicio Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.75.

Elicio Therapeutics Trading Down 1.6%

Shares of Elicio Therapeutics stock opened at $3.08 on Tuesday. Elicio Therapeutics has a 1 year low of $2.66 and a 1 year high of $16.00. The firm has a market cap of $58.80 million, a PE ratio of -1.42 and a beta of 1.30. The stock has a fifty day moving average price of $3.58 and a 200-day moving average price of $8.29. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77.

Elicio Therapeutics (NASDAQ:ELTX) last released its earnings results on Thursday, August 13th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11. Equities research analysts anticipate that Elicio Therapeutics will post -2.1 EPS for the current year.

Institutional Investors Weigh In On Elicio Therapeutics

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in Elicio Therapeutics by 186.8% in the 3rd quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after acquiring an additional 2,335 shares during the period. Raymond James Financial Inc. bought a new position in Elicio Therapeutics during the second quarter worth about $46,000. Deutsche Bank AG bought a new position in Elicio Therapeutics during the second quarter worth about $49,000. Bank of New York Mellon Corp purchased a new position in shares of Elicio Therapeutics in the second quarter worth about $62,000. Finally, Summit Financial LLC purchased a new position in shares of Elicio Therapeutics in the fourth quarter worth about $80,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Key Elicio Therapeutics News

Here are the key news stories impacting Elicio Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on Elicio Therapeutics, signaling continued confidence in the company’s longer-term prospects. The firm also raised its Q4 2026 EPS forecast to a loss of $0.37 from a prior estimate of $0.39 per share. HC Wainwright Reiterates Buy Rating for Elicio Therapeutics
• Neutral Sentiment: HC Wainwright projects continued losses in 2027, including EPS of negative $0.35 in the first quarter, negative $0.37 in the second quarter, negative $0.34 in the third quarter and negative $0.33 in the fourth quarter. Its full-year 2027 estimate is a loss of $1.38 per share.
• Negative Sentiment: The analyst cut its Q3 2026 EPS forecast to a loss of $0.44 from $0.39 and reduced its FY2026 estimate to a loss of $1.83 from $1.82. These revisions point to somewhat higher expected cash burn or operating losses in the near term.
• Negative Sentiment: Elicio remains an unprofitable biotechnology company, with consensus calling for a current-year loss of approximately $2.10 per share. Shares are trading below both their 50-day and 200-day moving averages and close to the 52-week low, indicating weak investor momentum.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.